射频消融治疗累及皮肤的复发性甲状腺癌的疗效与安全性初步报告
本回顾性病例系列研究纳入43例累及皮肤的复发性甲状腺癌患者共50个肿瘤,于2008年5月至2023年3月接受超声引导下射频消融治疗。1年技术有效率为72%(36/50,CI 59.6-84.4%),末次随访时临床成功率86%(44/50)、完全消失率54%(27/50)、平均体积缩小率77.3%±44.2%。作者认为射频消融可能是有前景的处理方式,表皮/真皮受累肿瘤皮肤烧伤风险可能高于皮下受累肿瘤,因此肿瘤延伸至表皮/真皮前早期干预可能更可取。
要点
- 1年技术有效率为72%(36/50,CI 59.6-84.4%),末次随访临床成功率86%(44/50)。
- 表皮/真皮受累与皮下受累肿瘤各疗效指标均无统计学差异(p值0.085至0.541)。
- 表皮/真皮受累肿瘤操作中皮肤烧伤发生率为4.9%(2/41,CI 0-11.3%),皮下受累者无皮肤烧伤。
核心结论
- 射频消融可能是有前景的累及皮肤复发性甲状腺癌处理方式,本初步研究中未报告主要并发症。
- 累及表皮/真皮的复发肿瘤皮肤烧伤风险可能高于累及皮下的肿瘤,因此肿瘤延伸至表皮/真皮前早期射频消融干预可能更可取。
研究设计与样本
- 回顾性病例系列研究,纳入43例累及皮肤的复发性甲状腺癌患者(平均年龄67.9±14.4岁,女性31例),共50个肿瘤,于2008年5月至2023年3月接受超声引导下射频消融治疗。
- 肿瘤按受累皮肤层分为表皮、真皮或皮下;共进行88次射频消融(平均1.8次,范围1-6次)。
主要发现
- 50个复发肿瘤中,表皮受累9个、真皮受累10个、皮下受累31个。
- 1年技术有效率为72%(36/50,CI 59.6-84.4%);末次随访(中位2.7年,四分位距1.1-4.5年)时临床成功率86%(44/50)、完全消失率54%(27/50)、平均体积缩小率77.3%±44.2%。
- 表皮/真皮受累组与皮下受累组比较:技术有效率57.9%(11/19)vs 80.6%(25/31),p=0.085;临床成功率78.9%(15/19)vs 90.3%(28/31),p=0.265;完全消失率42.1%(8/19)vs 51.6%(16/31),p=0.541;平均体积缩小率65.5% vs 84.6%,p=0.141;均无统计学差异。
- 表皮/真皮受累肿瘤操作中皮肤烧伤发生率为4.9%(2/41,CI 0-11.3%),皮下受累肿瘤操作中无皮肤烧伤;无患者发生危及生命或主要并发症。
临床怎么用
- 作者认为射频消融可能是有前景的累及皮肤复发性甲状腺癌处理方式,本初步研究中未报告主要并发症。
- 作者认为累及表皮/真皮的复发肿瘤皮肤烧伤风险可能高于累及皮下的肿瘤,因此肿瘤延伸至表皮/真皮前早期射频消融干预可能更可取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: This study assessed the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for treatment of skin-involving recurrent thyroid cancer. Methods: In this retrospective case series study, 43 patients (mean age: 67.9 ± 14.4 years; 31 females) with skin-involving recurrent thyroid cancer were treated with RFA for a total of 50 tumors between May 2008 and March 2023. The location of the tumor was classified into epidermis, dermis, or hypodermis on the basis of the involved skin layer. After RFA, the technique efficacy (absence of detectable vasculature and volume reduction at 12 months), clinical success (resolution of symptoms or cosmetic problems), volume reduction ratio (VRR), complete disappearance of tumor, and complications were assessed. Results: Of the 50 recurrent tumors, 9 involved the epidermis, 10 involved the dermis, and 31 involved the hypodermis. A total of 88 RFA sessions (mean, 1.8; range: 1-6) were performed. The technique efficacy at 1 year was 72% (36/50 [confidence interval or CI: 59.6-84.4%]). At the last follow-up (median [interquartile range]: 2.7 [1.1-4.5] years), the clinical success rate was 86% (44/50), the complete disappearance rate 54% (27/50), and the mean VRR 77.3% ± 44.2%. In a subgroup analysis comparing epidermis/dermis vs. hypodermis, there was no statistical difference in technique efficacy (57.9% [11/19] vs. 80.6% [25/31], p = 0.085), clinical success rate (78.9% [15/19] vs. 90.3% [28/31], p = 0.265), complete disappearance rate (42.1% [8/19] vs. 51.6% [16/31], p = 0.541), or mean VRR (65.5% vs. 84.6%, p = 0.141). Skin burns were observed in 4.9% per treatment session (2/41 [CI: 0-11.3%]) of epidermis/dermis-involving tumor procedures and none of the hypodermal tumor procedures. No patients experienced life-threatening or major complications. Conclusions: RFA might serve as a promising approach for managing skin-involving recurrent thyroid cancer, with no major complications reported in this preliminary study. Recurrent tumors involving the epidermis/dermis may pose a higher risk of skin burns than tumors involving the hypodermis. Early intervention with RFA before the tumor extends to the epidermis/dermis may thus be preferable.
引用
- Moon HH, Baek JH, Chung SR, et al. Preliminary Report Examining Efficacy and Safety of Radiofrequency Ablation for the Treatment of Skin-Involving Recurrent Thyroid Cancer. Thyroid. 2024. PMID: 39688248. doi:10.1089/thy.2024.0339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。